Level C· Early human research exploring benefits
A systematic review of autologous adipose-derived stromal vascular fraction (SVF) for the treatment of acute cutaneous wounds
Lee M.H., Kang B.Y., Wong C.C., Alam M.
Evaluated the literature on efficacy and safety of autologous SVF for acute cutaneous wounds in humans.
Level C· Early human research exploring benefitsEvidence level of this study
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
- Study type
- Systematic Review
- Journal
- Archives of Dermatological Research (2022)
- Country
- United States
- Sample size
- —
- Follow-up
- Varied across included studies
- PMID
- 34047823
- DOI
- 10.1007/s00403-021-02242-x
What was studied
Whether SVF accelerates healing of acute cutaneous wounds and how safe it is.
Methods
- • Systematic review of major medical databases.
Key findings
- • Human data remain limited and most studies are small.
- • No concerning safety signals emerged from the included studies.
Limitations
- • Heterogeneous wound types and outcome measures.
- • Lack of adequately powered randomized trials.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Limited follow-up cannot indicate long-term outcomes.
Clinical interpretation
Acute wounds remain a less-evidenced indication than chronic wounds.
Evidence level: Early human research exploring benefits